The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
Open accessAbstract
BACKGROUND: Opioid-induced constipation is common and debilitating. We investigated the efficacy and safety of naloxegol, an oral, peripherally acting, μ-opioid receptor antagonist, for the treatment of opioid-induced constipation. METHODS: In two identical phase 3, double-blind studies (study 04, 652 participants; study 05, 700 participants), outpatients with noncancer pain and opioid-induced constipation were randomly assigned to receive a daily dose of 12.5 or 25 mg of naloxegol or placebo. The primary end point was the 12-week response rate (≥3 spontaneous bowel movements per week and an increase from baseline of ≥1 spontaneous bowel movements for ≥9 of 12 weeks and for ≥3 of the final 4 weeks) in the intention-to-treat population. The key secondary end points were the response rate in the subpopulation of patients with an inadequate response to laxatives before enrollment, time to first postdose spontaneous bowel movement, and mean number of days per week with one or more spontaneous bowel movements. RESULTS: Response rates were significantly higher with 25 mg of naloxegol than with placebo (intention-to-treat population: study 04, 44.4% vs. 29.4%, P=0.001; study 05, 39.7% vs. 29.3%, P=0.02; patients with an inadequate response to laxatives: study 04, 48.7% vs. 28.8%, P=0.002; study 05, 46.8% vs. 31.4%, P=0.01); in study 04, response rates were also higher in the group treated with 12.5 mg of naloxegol (intention-to-treat population, 40.8% vs. 29.4%, P=0.02; patients with an inadequate response to laxatives, 42.6% vs. 28.8%, P=0.03). A shorter time to the first postdose spontaneous bowel movement and a higher mean number of days per week with one or more spontaneous bowel movements were observed with 25 mg of naloxegol versus placebo in both studies (P<0.001) and with 12.5 mg of naloxegol in study 04 (P<0.001). Pain scores and daily opioid dose were similar among the three groups. Adverse events (primarily gastrointestinal) occurred most frequently in the groups treated with 25 mg of naloxegol. CONCLUSIONS: Treatment with naloxegol, as compared with placebo, resulted in a significantly higher rate of treatment response, without reducing opioid-mediated analgesia. (Funded by AstraZeneca; KODIAC-04 and KODIAC-05 ClinicalTrials.gov numbers, NCT01309841 and NCT01323790, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Opioids in chronic non-cancer pain: systematic review of efficacy and safety
Kalso, E., Edwards, J. E., Moore, A. R., & McQuay, H. J. (2004) · Pain · doi:10.1016/j.pain.2004.09.019 · Cited by 1,216
Incidence, Prevalence, and Management of Opioid Bowel Dysfunction
Pappagallo, M. (2001) · The American Journal of Surgery · doi:10.1016/s0002-9610(01)00782-6 · Cited by 531
Bell, T. J., Panchal, S. J., Miaskowski, C., Bolge, S. C., Milanova, T., & Williamson, R. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2008.00495.x · Cited by 500
Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden
Panchal, S. J., Müller-Schwefe, P., & Wurzelmann, J. I. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01415.x · Cited by 325
Opioid-Induced Constipation: Challenges and Therapeutic Opportunities
Camilleri, M. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.30 · Cited by 262
Treatment of opioid-induced constipation with oral naloxone: A pilot study
Culpepper-Morgan, J. A., Inturrisi, C. E., Portenoy, R. K., Foley, K., Houde, R. W., Marsh, F., & Kreek, M. J. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.106 · Cited by 208
Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain
tuteja, A. K., biskupiak, J., stoddard, G. J., & lipman, A. G. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01458.x · Cited by 179
THE MORPHINE ABSTINENCE SYNDROME, ITS NATURE AND TREATMENT
Himmelsbach, C. K. (1941) · Annals of Internal Medicine · doi:10.7326/0003-4819-15-5-829 · Cited by 145
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs
Faassen, F. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00372-7 · Cited by 132
Webster, L. R., Dhar, S., Eldon, M. A., Masuoka, L. K., Lappalainen, J., & Sostek, M. B. (2013) · Pain · doi:10.1016/j.pain.2013.04.024 · Cited by 117
Self-citationMeeting the Challenges of Opioid-Induced Constipation in Chronic Pain Management – A Novel Approach
Reimer, K., Hopp, M., Zenz, M. W., Maier, C., Holzer, P. D., Mikus, G., Bosse, B., Smith, K. J., Buschmann-Kramm, C., & Leyendecker, P. (2008) · Pharmacology · doi:10.1159/000165778 · Cited by 81
Novel opioid antagonists for opioid-induced bowel dysfunction
Diego, L., Atayee, R. S., Helmons, P., et al. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.592830 · Cited by 70
New approaches to the treatment of opioid-induced constipation.
Holzer, P. D. (2008) · PubMed · Cited by 41
Alvimopan for postoperative ileus
Bream‐Rouwenhorst, H. R., & Cantrell, M. A. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080445 · Cited by 34
Cited by
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Self-citationThe evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy152 · Cited by 954
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Swarm, R. A., Paice, J. A., Anghelescu, D. L., Are, M., Bruce, J. Y., Buga, S., Chwistek, M., Cleeland, C., Craig, D., Gafford, E., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0038 · Cited by 621
Diagnosis and management of chronic constipation in adults
Rao, S. S. C., Rattanakovit, K., & Patcharatrakul, T. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.53 · Cited by 337
Metadata
- Authors
- Chey, W. D., Webster, L., Sostek, M., Lappalainen, J., Barker, P. N., & Tack, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-06-19
- Volume
- 370
- Issue
- 25
- Pages
- 2387-2396
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1996075855
- Cited by
- 330
- References
- 15
- FWCI
- 39.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.